Highest-materiality recent filing
Lipocine Q2 net loss $2.6M; Phase 3 PPD trial misses primary endpoint
Net loss of $2.6M ($0.32 per share) vs $2.2M loss ($0.41 per share) in Q2 2025.
Lipocine Presents Phase 3 Data for LPCN 1154 (Oral Brexanolone) for Postpartum Depression at ASCP
May 26, 2026: Company highlighted results from placebo-controlled Phase 3 trial of LPCN 1154 for PPD at ASCP Annual Meeting.
Lipocine LPCN 1154 Phase 3 data accepted for oral presentation at 2026 ASCP meeting
Phase 3 data for LPCN 1154 (oral brexanolone) for postpartum depression accepted for oral and poster presentation at ASCP Annual Meeting May 26-29, 2026 in Miami, FL.
Lipocine misses Q1 EPS estimates; LPCN 1154 PPD Phase 3 fails primary endpoint
Net loss of $3.7M ($0.52/share) vs $1.9M loss ($0.35) in Q1 2025; cash $24.7M.
Lipocine's LPCN 1154 Phase 3 PPD trial misses primary endpoint; post hoc signals
Primary endpoint not met: no statistically significant HAM-D17 reduction vs placebo at hour 60 in full population (N=90).
Lipocine reports FY2025 net loss of $9.6M; cash $14.9M; PPD Phase 3 topline due April 2026
Net loss of $9.6M ($1.69/diluted) vs $8K net income in FY2024; revenue fell to $2.0M from $11.2M.
Lipocine files $50M ATM equity facility with A.G.P./Alliance Global Partners
Filed prospectus supplement on Feb 26, 2026 for sale of up to $50M common stock via ATM.
Lipocine completes last patient last visit in Phase 3 trial of LPCN 1154 for PPD
Last patient completed final visit in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression.
90 patients randomized in double-blind, placebo-controlled Phase 3 trial of LPCN 1154 (oral brexanolone) for PPD.
Lipocine: Phase 3 PPD trial passes second DSMB safety review; topline data due Q2 2026
DSMB reviewed safety data from 82 randomized patients; recommended trial continue without modification.
Lipocine reports promising interim safety for LPCN 1154 in Phase 3 PPD trial; topline Q2 2026
DSMB review after one-third of planned 80 participants (n=30) recommended continuation as planned without modification.
Lipocine Q3 net loss widens to $3.2M; cash drops to $15.1M; PPD trial on track
Net loss of $3.2M ($0.59/sh) vs $2.2M loss ($0.44/sh) in Q3 2024.
Lipocine LPCN 1154 Phase 3 PPD trial: 1/3 randomized; topline 2Q26; DSMB review 4Q25
One-third of planned patients randomized in LPCN 1154 Phase 3 trial for postpartum depression.
Lipocine delays LPCN 2401 POC study, seeks FDA clarity on endpoints
Received IND clearance for LPCN 2401 as adjunct to GLP-1 therapy.
Lipocine Q2 net loss narrows to $2.2M; Phase 3 PPD study underway
Net loss of $2.2M ($0.41/diluted share) vs $3.1M loss year ago; cash $17.9M at quarter end.
First patient dosed in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression; top line data expected Q2 2026.
Lipocine's partner Verity Pharma files New Drug Submission for TLANDO in Canada
Over 700,000 annual TRT prescriptions in Canada, representing large opportunity.
Lipocine Q1 net loss $1.9M; starts Phase 3 for PPD drug LPCN 1154
Net loss $1.9M ($0.35 diluted share) vs net income $3.5M ($0.66) in Q1 2024.
Lipocine licenses TLANDO in Brazil; oral testosterone market grew 34% CAGR 2019-2023
Exclusive license and supply agreement with Aché Laboratórios for TLANDO in Brazil.
Lipocine initiates Phase 3 outpatient PPD trial of LPCN 1154; dosing expected Q2 2025
Initiation of randomized, blinded, placebo-controlled Phase 3 trial of LPCN 1154 for PPD; first patient dosing expected Q2 2025.
Lipocine reports near-breakeven 2024; FDA requires Phase 3 for oral brexanolone
Net income of ~$8,400 vs net loss of $16.4M in 2023; revenue of $11.2M from license/royalty fees.
FDA removes Boxed Warning for testosterone products after TRAVERSE trial benefits Lipocine
FDA removes Boxed Warning on cardiovascular risk for all testosterone products based on TRAVERSE trial.
On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.
On April 11, 2022, the Board of Directors of the Company expanded the Board of Directors to six members and appointed Dr. Jill M. Jene and Dr. Spyros Papapetropoulos as directors, effective immediately.
On April 11, 2022, the Board of Directors of the Company expanded the Board of Directors to six members and appointed Dr. Jill M. Jene and Dr. Spyros Papapetropoulos as directors, effective immediately.
As previously disclosed, on January 19, 2022, the Board of Directors of the Company appointed Krista Fogarty, the Company’s Corporate Controller, to also serve as the Principal Accounting Officer of the Company.
On January 17, 2022, Morgan Brown provided Lipocine, Inc. (the “Company”) with notice of his intent to resign from his position as Executive Vice President and Chief Financial Officer of the Company, effective as of January 31, 2022.
Upon the effective date of Mr. Brown’s resignation, Mahesh Patel, the Company’s President and Chief Executive Officer, will serve as the Company’s Principal Financial Officer on an interim basis until Mr. Brown’s successor is appointed.
On January 19, 2022, the Board of Directors of the Company appointed Krista Fogarty, the Company’s Corporate Controller, to also serve as the Principal Accounting Officer of the Company.
Max materiality 0.90 · Median 0.50 · Most common event other_material